JP2017519018A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017519018A5 JP2017519018A5 JP2016574175A JP2016574175A JP2017519018A5 JP 2017519018 A5 JP2017519018 A5 JP 2017519018A5 JP 2016574175 A JP2016574175 A JP 2016574175A JP 2016574175 A JP2016574175 A JP 2016574175A JP 2017519018 A5 JP2017519018 A5 JP 2017519018A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- protein
- liquid
- therapeutic
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000009472 formulation Methods 0.000 claims 27
- 239000000203 mixture Substances 0.000 claims 27
- 102000004169 proteins and genes Human genes 0.000 claims 16
- 108090000623 proteins and genes Proteins 0.000 claims 16
- 230000001225 therapeutic effect Effects 0.000 claims 12
- 239000012669 liquid formulation Substances 0.000 claims 10
- 239000007788 liquid Substances 0.000 claims 7
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims 3
- 229960001948 caffeine Drugs 0.000 claims 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000003672 processing method Methods 0.000 claims 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 108010011485 Aspartame Proteins 0.000 claims 1
- 108010003272 Hyaluronate lyase Proteins 0.000 claims 1
- 102000001974 Hyaluronidases Human genes 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-N Tyramine Natural products NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 claims 1
- 235000010358 acesulfame potassium Nutrition 0.000 claims 1
- 229960004998 acesulfame potassium Drugs 0.000 claims 1
- 239000000619 acesulfame-K Substances 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 239000000605 aspartame Substances 0.000 claims 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims 1
- 235000010357 aspartame Nutrition 0.000 claims 1
- 229960003438 aspartame Drugs 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 238000005119 centrifugation Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 229960002773 hyaluronidase Drugs 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 229960004194 lidocaine Drugs 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims 1
- 229960004919 procaine Drugs 0.000 claims 1
- 238000005086 pumping Methods 0.000 claims 1
- 235000019204 saccharin Nutrition 0.000 claims 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims 1
- 229940081974 saccharin Drugs 0.000 claims 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 229960003732 tyramine Drugs 0.000 claims 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-O tyraminium Chemical compound [NH3+]CCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-O 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020039681A JP6983266B2 (ja) | 2014-06-20 | 2020-03-09 | タンパク質配合物のための粘度低減賦形剤化合物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462014784P | 2014-06-20 | 2014-06-20 | |
| US62/014,784 | 2014-06-20 | ||
| US201462083623P | 2014-11-24 | 2014-11-24 | |
| US62/083,623 | 2014-11-24 | ||
| US201562136763P | 2015-03-23 | 2015-03-23 | |
| US62/136,763 | 2015-03-23 | ||
| PCT/US2015/036899 WO2015196187A1 (en) | 2014-06-20 | 2015-06-22 | Viscosity-reducing excipient compounds for protein formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020039681A Division JP6983266B2 (ja) | 2014-06-20 | 2020-03-09 | タンパク質配合物のための粘度低減賦形剤化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017519018A JP2017519018A (ja) | 2017-07-13 |
| JP2017519018A5 true JP2017519018A5 (enExample) | 2018-08-02 |
| JP6674910B2 JP6674910B2 (ja) | 2020-04-01 |
Family
ID=54936144
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016574175A Expired - Fee Related JP6674910B2 (ja) | 2014-06-20 | 2015-06-22 | タンパク質配合物のための粘度低減賦形剤化合物 |
| JP2020039681A Expired - Fee Related JP6983266B2 (ja) | 2014-06-20 | 2020-03-09 | タンパク質配合物のための粘度低減賦形剤化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020039681A Expired - Fee Related JP6983266B2 (ja) | 2014-06-20 | 2020-03-09 | タンパク質配合物のための粘度低減賦形剤化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (6) | US20160074515A1 (enExample) |
| EP (2) | EP3160484B1 (enExample) |
| JP (2) | JP6674910B2 (enExample) |
| KR (2) | KR20220153668A (enExample) |
| CN (1) | CN106535918B (enExample) |
| BR (1) | BR112016029906A8 (enExample) |
| CA (1) | CA2951716C (enExample) |
| ES (1) | ES2965722T3 (enExample) |
| WO (2) | WO2015196091A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
| US20160074515A1 (en) | 2014-06-20 | 2016-03-17 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
| US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
| WO2021108427A1 (en) * | 2019-11-26 | 2021-06-03 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
| AU2015325055B2 (en) | 2014-10-01 | 2021-02-25 | Eagle Biologics, Inc. | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
| EP4324482A2 (en) * | 2015-10-23 | 2024-02-21 | Comera Life Sciences, Inc. | Excipient compounds for biopolymer formulations |
| EP3484520A4 (en) | 2016-07-13 | 2020-07-29 | Reform Biologics, LLC | STABILIZING EXCIPIENTS FOR THERAPEUTIC PROTEIN FORMULATIONS |
| SG11201900895QA (en) | 2016-08-18 | 2019-02-27 | Regeneron Pharma | Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy |
| MA46466A (fr) * | 2016-10-06 | 2019-08-14 | Amgen Inc | Formulations pharmaceutiques de protéines à viscosité réduite |
| AU2017364077A1 (en) | 2016-11-22 | 2019-06-20 | Elektrofi, Inc. | Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof |
| KR102572453B1 (ko) * | 2017-02-16 | 2023-08-29 | 코메라 라이프 사이언시스, 인코포레이티드 | 단백질 가공 처리를 위한 부형제 화합물 |
| AU2018258676B2 (en) * | 2017-04-28 | 2024-09-19 | Amgen Inc. | N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides |
| US12257343B2 (en) | 2017-04-28 | 2025-03-25 | Amgen Inc. | Excipients to reduce the viscosity of antibody formulations and formulation compositions |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| SG11201909955XA (en) | 2017-05-02 | 2019-11-28 | Merck Sharp & Dohme | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
| EP3624846B1 (en) * | 2017-05-16 | 2024-08-07 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity including a combination of nicotinic acid and tryoptophan |
| AU2018306303A1 (en) | 2017-07-25 | 2020-02-20 | Elektrofi, Inc. | Formation of particles including agents |
| SG11202000952PA (en) * | 2017-08-03 | 2020-02-27 | Jazz Pharmaceuticals Ireland Ltd | Formulations comprising a nucleic acid in a high concentration |
| AU2018328015A1 (en) | 2017-09-05 | 2020-03-05 | Merck Sharp & Dohme Corp. | Compounds for reducing the viscosity of biological formulations |
| WO2019106206A1 (en) | 2017-12-01 | 2019-06-06 | Fyb 202 Project Gmbh | Stable, low viscosity, high concentration liquid formulations of an anti-il-12/23p40 antibody |
| KR20230018549A (ko) * | 2018-03-07 | 2023-02-07 | 코메라 라이프 사이언시스, 인코포레이티드 | 단백질 제형을 위한 부형제 화합물 |
| AU2019254483B2 (en) | 2018-04-16 | 2025-02-27 | Merck Patent Gmbh | Viscosity reduction of highly concentrated protein formulations |
| US12115262B2 (en) | 2018-05-24 | 2024-10-15 | Elektrofi, Inc. | Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof |
| EP3852723B1 (en) | 2018-09-20 | 2025-11-05 | ACADIA Pharmaceuticals Inc. | Stable intranasal formulations of carbetocin |
| AU2019345313A1 (en) | 2018-09-20 | 2021-03-18 | Levo Therapeutics, Inc. | Carbetocin drug product and process for preparing same |
| EP3876990A4 (en) | 2018-11-07 | 2023-09-06 | Merck Sharp & Dohme LLC | CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES |
| EP3886909A4 (en) * | 2018-11-29 | 2023-03-29 | Comera Life Sciences, Inc. | ADDITOR COMPOUNDS FOR PROTEIN PROCESSING |
| AU2020214626B2 (en) | 2019-01-31 | 2025-10-16 | Elektrofi, Inc. | Particle formation and morphology |
| JP7781743B2 (ja) | 2019-09-13 | 2025-12-08 | エレクトロフィ，インコーポレイテッド | 疾患の処置のための治療用生物学的作用剤の送達のための組成物及び方法 |
| JP2023522627A (ja) | 2020-04-17 | 2023-05-31 | エレクトロフィ，インコーポレイテッド | 連続的な液滴形成及び脱水によって粒子を形成する方法 |
| CA3187322A1 (en) | 2020-07-13 | 2022-01-20 | Merck Patent Gmbh | Viscosity reducing excipients and combinations thereof for highly concentrated protein formulations |
| EP4319795A4 (en) * | 2021-04-09 | 2025-03-05 | Avantor Performance Materials, LLC | Performance-enhancing excipients and methods of reducing viscosity and increasing stability of biologic formulations |
| MX2024008243A (es) | 2021-12-30 | 2024-09-04 | Baxter Int | Soluciones de fibrinogeno y trombina para un sellador de fibrina y un kit de sellador de fibrina. |
| WO2023217813A2 (en) * | 2022-05-12 | 2023-11-16 | Merck Patent Gmbh | Excipients for purification and virus filtration of biological fluids |
| KR20230167968A (ko) * | 2022-06-03 | 2023-12-12 | 주식회사 녹십자홀딩스 | 점도 감소 부형제 조성물 및 이를 포함하는 저점도 고농축 단백질 제형 |
| KR20250152101A (ko) | 2023-03-13 | 2025-10-22 | 하이델베르크 파마 리서치 게엠베하 | 암 치료에의 사용을 위한 피하 투여 항체-약물 접합체 |
| WO2025131987A1 (en) | 2023-12-18 | 2025-06-26 | Merck Patent Gmbh | Viscosity reducing excipients and combinations thereof for liquid compositions comprising a protein |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2230965A (en) | 1940-06-14 | 1941-02-04 | American Cyanamid Co | Process of preparing guanyl taurine |
| DE3128117A1 (de) | 1980-07-29 | 1982-03-11 | Yamanouchi Pharmaceutical Co., Ltd., Tokyo | Neue phenyl-aethylaminderivate, verfahren zu ihrer herstellung |
| US4548827A (en) * | 1982-03-30 | 1985-10-22 | General Foods Corporation | Separate recovery of caffeine and coffee solids adsorbed on activated carbon |
| CA1206370A (en) * | 1982-08-17 | 1986-06-24 | Ajinomoto Co., Inc. | Stabilized aspartame compositions |
| US5164214A (en) * | 1987-12-10 | 1992-11-17 | Rudolf-Wild Gmbh & Co. Kg | Sweetening agent |
| WO1989009402A1 (fr) | 1988-03-30 | 1989-10-05 | Toray Industries, Inc. | PREPARATION LYOPHILISEE CONTENANT UN ANTICORPS DE L'INTERFERON beta ANTIHUMAIN MARQUE PAR UNE ENZYME ET KIT D'ANALYSE ENZYMATIQUE CONTENANT CETTE PREPARATION |
| US5849700A (en) | 1991-12-20 | 1998-12-15 | Novo Nordisk A/S | Pharmaceutical formulation |
| DE4344824C1 (de) | 1993-12-28 | 1995-08-31 | Immuno Ag | Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung |
| GB9418092D0 (en) | 1994-09-08 | 1994-10-26 | Red Cross Found Cent Lab Blood | Organic compounds |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US5900416A (en) | 1996-02-01 | 1999-05-04 | Anthea Enterprises Incorporated | Aqueous caffeine dosage forms |
| KR100236393B1 (ko) | 1996-02-02 | 1999-12-15 | 나까니시 히로유끼 | 사람성장호르몬을 함유하는 의약제제 |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| CN100389821C (zh) | 1999-10-04 | 2008-05-28 | 希龙公司 | 稳定化的含多肽的液体药物组合物 |
| US20040081702A1 (en) * | 2000-04-14 | 2004-04-29 | Kim Christopher M. | Bee venom treatment without the sting |
| IL155002A0 (en) | 2000-10-12 | 2003-10-31 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
| US8703126B2 (en) * | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| ATE454137T1 (de) | 2001-07-25 | 2010-01-15 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
| JP2005523882A (ja) | 2001-10-16 | 2005-08-11 | アールエックスキネティックス，インコーポレイテッド | 高濃度タンパク質製剤および製造の方法 |
| US20030138417A1 (en) | 2001-11-08 | 2003-07-24 | Kaisheva Elizabet A. | Stable liquid pharmaceutical formulation of IgG antibodies |
| CN1671741A (zh) | 2002-06-21 | 2005-09-21 | 拜奥根Idec公司 | 浓缩抗体的缓冲剂制剂及其使用方法 |
| US7041088B2 (en) | 2002-10-11 | 2006-05-09 | Ethicon, Inc. | Medical devices having durable and lubricious polymeric coating |
| CN100361599C (zh) | 2002-10-23 | 2008-01-16 | 克尔塞根控股有限公司 | 抗氧化组合物 |
| AU2003293543A1 (en) | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
| KR20040084168A (ko) | 2003-03-26 | 2004-10-06 | 아미코젠주식회사 | 피니톨 또는 카이로이노시톨을 포함하는 간 질환 예방 및치료용 조성물 |
| DK1610820T4 (da) | 2003-04-04 | 2013-11-04 | Genentech Inc | Høj-koncentration antistof- og proteinformuleringer |
| US20050158303A1 (en) | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
| DE10325198B4 (de) | 2003-06-04 | 2007-10-25 | Clariant Produkte (Deutschland) Gmbh | Verwendung von alkoxylierten vernetzten Polyglycerinen als biologisch abbaubare Emulsionsspalter |
| EP1504671A1 (en) * | 2003-07-30 | 2005-02-09 | Nestec S.A. | Controlled delivery of caffeine from high-caffeinated coffee beverages made from soluble powder |
| AU2004324323A1 (en) * | 2003-10-31 | 2006-06-15 | Robarts Research Institute | Methods and formulations for protecting cells, and for treating diseases and conditions by optimising the intracellular concentration of NAD |
| EP1532983A1 (en) | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Immunoglobulin preparations having increased stability |
| US20050186183A1 (en) | 2003-12-08 | 2005-08-25 | Deangelo Joseph | Stabilized products, processes and devices for preparing same |
| WO2006119054A2 (en) * | 2005-04-29 | 2006-11-09 | E. I. Du Pont De Nemours And Company | Multi-step process for the manufacture of therapeutic protein |
| CA2634547C (en) | 2005-12-20 | 2016-10-11 | Bristol-Myers Squibb Company | Stable ctla4 formulation for subcutaneous administration |
| WO2007076062A2 (en) | 2005-12-21 | 2007-07-05 | Wyeth | Protein formulations with reduced viscosity and uses thereof |
| US8025915B2 (en) | 2006-01-11 | 2011-09-27 | Schott Ag | Method of preparing a macromolecule deterrent surface on a pharmaceutical package |
| AU2007212147A1 (en) | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
| NZ570558A (en) | 2006-03-10 | 2012-06-29 | Next Proteins Inc | Protein drink and method of making same |
| CN101442915A (zh) * | 2006-03-10 | 2009-05-27 | 内克斯特蛋白质公司 | 蛋白饮料及其制备方法 |
| TWI543988B (zh) | 2006-03-16 | 2016-08-01 | 科學製藥股份有限公司 | 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物 |
| AU2007234612B2 (en) | 2006-12-14 | 2013-06-27 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein stabilization formulations |
| GB0700523D0 (en) | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
| WO2009055427A2 (en) * | 2007-10-22 | 2009-04-30 | Becton, Dickinson And Company | Methods for evaluating the aggregation of a protein in a suspension including organopolysiloxane and medical articles coated with organopolysiloxane containing a protein solution |
| US7678764B2 (en) | 2007-06-29 | 2010-03-16 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein formulations for use at elevated temperatures |
| CA2690773C (en) | 2007-07-10 | 2013-09-17 | Medy-Tox, Inc. | Pharmaceutical liquid composition of botulinum toxin with improved stability |
| US20090047328A1 (en) | 2007-08-16 | 2009-02-19 | Peter Cunningham | Caffeine delivery systems |
| CA2701032C (en) | 2007-09-27 | 2021-01-26 | Amgen Inc. | Pharmaceutical formulations |
| WO2009065126A2 (en) * | 2007-11-16 | 2009-05-22 | Boston Protein Solutions | Excipients for protein stabilization |
| TWI661833B (zh) | 2007-11-30 | 2019-06-11 | 百慕達商艾伯維生物技術有限責任公司 | 蛋白質調配物及製造其之方法 |
| AU2008343052A1 (en) | 2007-12-21 | 2009-07-09 | Lyotropic Therapeutics, Inc. | Stabilized formulations of peptides and proteins |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| BRPI0911048A2 (pt) | 2008-04-14 | 2015-12-29 | Atrm Llc | formulações líquidas tamponadas de gdf-5 |
| WO2009141433A1 (en) * | 2008-05-23 | 2009-11-26 | Novo Nordisk Health Care Ag | Low viscosity compositions comprising a pegylated gla-domain containing protein |
| KR20110091678A (ko) | 2008-10-20 | 2011-08-12 | 아보트 러보러터리즈 | 단백질 ａ 친화성 크로마토그래피를 이용한 항체의 분리 및 정제 |
| EP2350273B1 (en) | 2008-10-31 | 2016-04-06 | AERase, Inc. | Compositions of engineered human arginases and methods for treating cancer |
| US8980610B2 (en) | 2008-11-20 | 2015-03-17 | Biogen Idec Ma Inc. | Arginine inactivation of viruses |
| CA2754528A1 (en) | 2009-03-06 | 2010-09-10 | Genetech, Inc. | Antibody formulation |
| WO2011008495A2 (en) | 2009-06-29 | 2011-01-20 | The Board Of Regents Of The University Of Texas System | Arginase formulations and methods |
| US9084743B2 (en) | 2009-09-17 | 2015-07-21 | Baxter International Inc. | Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof |
| CN102939106B (zh) | 2010-02-24 | 2016-06-29 | 艾瑞克有限公司 | 蛋白质制剂 |
| WO2011104381A2 (en) | 2010-02-26 | 2011-09-01 | Novo Nordisk A/S | Stable antibody containing compositions |
| RU2626512C2 (ru) * | 2010-03-01 | 2017-07-28 | Цитодин, Инк. | Концентрированные белковые фармацевтические составы и их применение |
| US20130171128A1 (en) | 2010-03-02 | 2013-07-04 | Amgen Inc. | Reducing viscosity of pharmaceutical formulations |
| JP2013525484A (ja) | 2010-05-03 | 2013-06-20 | ジェネンテック， インコーポレイテッド | タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法 |
| SMT202000095T1 (it) * | 2010-05-14 | 2020-03-13 | Amgen Inc | Formulazioni di anticorpi anti-sclerostina ad alta concentrazione |
| MY161390A (en) | 2010-06-24 | 2017-04-14 | Genentech Inc | Compositions and methods containing alkylglycosides for stabilizing protein-containing formulations |
| JP5710311B2 (ja) | 2011-02-18 | 2015-04-30 | 株式会社日立製作所 | 添加培地の添加制御方法、及び当該方法を用いた細胞培養装置 |
| CN105853348B (zh) | 2011-03-10 | 2019-08-30 | Xeris药物公司 | 肠胃外注射用稳定溶液 |
| BR112014009031A2 (pt) | 2011-10-18 | 2017-05-09 | Coherus Biosciences Inc | formulações de etanercept estabilizadas com íons de metais |
| CA2951856A1 (en) | 2011-10-28 | 2013-05-02 | Integritybio Inc. | Protein formulations containing amino acids |
| HK1201857A1 (en) | 2011-10-31 | 2015-09-11 | F. Hoffmann-La Roche Ag | Antibody formulations |
| MY188825A (en) | 2012-05-18 | 2022-01-06 | Genentech Inc | High-concentration monoclonal antibody formulations |
| SG11201407812SA (en) | 2012-05-31 | 2014-12-30 | Agency Science Tech & Res | Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives |
| EP2682168A1 (en) | 2012-07-02 | 2014-01-08 | Millipore Corporation | Purification of biological molecules |
| US20140055254A1 (en) | 2012-08-03 | 2014-02-27 | Christopher Jack Adams | Collision avoidance system for vehicles |
| US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
| FR2995214B1 (fr) | 2012-09-10 | 2014-11-21 | Adocia | Solution a viscosite reduite de proteine a concentration elevee |
| JP6026002B2 (ja) | 2012-11-27 | 2016-11-16 | アルテオジェン インコーポレイテッド | タンパク質とＦｃドメインを融合した融合タンパク質の安定化用組成物 |
| MX350569B (es) | 2012-12-03 | 2017-09-11 | Landsteiner Scient S A De C V | Composicion farmaceutica estable para el tratamiento de osteoporosis. |
| HK1220120A1 (zh) | 2013-03-15 | 2017-04-28 | Ansun Biopharma, Inc. | 制造注射蛋白质微粒悬浮液的方法 |
| US9342374B2 (en) * | 2013-06-28 | 2016-05-17 | Dell Products, L.P. | Method of scheduling threads for execution on multiple processors within an information handling system |
| IL312865B2 (en) * | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| WO2021072050A1 (en) | 2019-10-08 | 2021-04-15 | Reform Biologics, Llc | Excipient compounds for protein formulations |
| US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
| US20160074515A1 (en) * | 2014-06-20 | 2016-03-17 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
| WO2021108427A1 (en) | 2019-11-26 | 2021-06-03 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
| US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
| AU2015325055B2 (en) | 2014-10-01 | 2021-02-25 | Eagle Biologics, Inc. | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
| CA2969974C (en) | 2014-12-15 | 2020-08-04 | The Regents Of The University Of Michigan | Small molecule inhibitors of egfr and pi3k |
| US9649364B2 (en) | 2015-09-25 | 2017-05-16 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic formulations in aprotic polar solvents |
| EP4324482A2 (en) | 2015-10-23 | 2024-02-21 | Comera Life Sciences, Inc. | Excipient compounds for biopolymer formulations |
| EP3484520A4 (en) | 2016-07-13 | 2020-07-29 | Reform Biologics, LLC | STABILIZING EXCIPIENTS FOR THERAPEUTIC PROTEIN FORMULATIONS |
| KR102572453B1 (ko) | 2017-02-16 | 2023-08-29 | 코메라 라이프 사이언시스, 인코포레이티드 | 단백질 가공 처리를 위한 부형제 화합물 |
| EP3624846B1 (en) | 2017-05-16 | 2024-08-07 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity including a combination of nicotinic acid and tryoptophan |
| WO2019036619A1 (en) | 2017-08-18 | 2019-02-21 | Reform Biologics, Llc | STABILIZING EXCIPIENTS FOR FORMULATIONS OF THERAPEUTIC PROTEIN |
| KR20230018549A (ko) | 2018-03-07 | 2023-02-07 | 코메라 라이프 사이언시스, 인코포레이티드 | 단백질 제형을 위한 부형제 화합물 |
| EP3886909A4 (en) | 2018-11-29 | 2023-03-29 | Comera Life Sciences, Inc. | ADDITOR COMPOUNDS FOR PROTEIN PROCESSING |
| WO2022056220A2 (en) | 2020-09-11 | 2022-03-17 | Reform Biologics, Inc. | Excipient compounds for protein formulations |
-
2015
- 2015-06-19 US US14/744,847 patent/US20160074515A1/en not_active Abandoned
- 2015-06-19 WO PCT/US2015/036724 patent/WO2015196091A1/en not_active Ceased
- 2015-06-22 ES ES15809600T patent/ES2965722T3/es active Active
- 2015-06-22 CA CA2951716A patent/CA2951716C/en active Active
- 2015-06-22 CN CN201580039834.6A patent/CN106535918B/zh not_active Expired - Fee Related
- 2015-06-22 BR BR112016029906A patent/BR112016029906A8/pt not_active Application Discontinuation
- 2015-06-22 EP EP15809600.8A patent/EP3160484B1/en active Active
- 2015-06-22 JP JP2016574175A patent/JP6674910B2/ja not_active Expired - Fee Related
- 2015-06-22 KR KR1020227038231A patent/KR20220153668A/ko not_active Ceased
- 2015-06-22 KR KR1020177001786A patent/KR102463682B1/ko active Active
- 2015-06-22 WO PCT/US2015/036899 patent/WO2015196187A1/en not_active Ceased
- 2015-06-22 EP EP23194097.4A patent/EP4309643A3/en not_active Withdrawn
- 2015-12-11 US US14/966,549 patent/US9605051B2/en not_active Expired - Fee Related
-
2017
- 2017-02-16 US US15/434,379 patent/US9867881B2/en active Active
-
2019
- 2019-02-25 US US16/284,583 patent/US11660343B2/en active Active
-
2020
- 2020-03-09 JP JP2020039681A patent/JP6983266B2/ja not_active Expired - Fee Related
-
2022
- 2022-09-16 US US17/933,071 patent/US11672865B2/en active Active
-
2023
- 2023-04-19 US US18/303,082 patent/US20230381318A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017519018A5 (enExample) | ||
| ES2684921T3 (es) | Formulación líquida de polipéptidos que contienen un dominio Fc de una inmunoglobulina | |
| EP2822591B1 (en) | Pharmaceutical formulations of tnf-alpha antibodies | |
| RU2016113283A (ru) | Жидкие составы белков, содержащие средства для снижения вязкости | |
| FI3484446T3 (fi) | Vasta-ainekoostumuksia | |
| EA201790568A1 (ru) | Применение двойного агониста рецепторов glp-1/глюкагона пролонгированного действия для лечения неалкогольной жировой болезни печени | |
| JP2016530321A5 (ja) | イオン性液体を含有する注射用液状タンパク質製剤およびその使用 | |
| KR20140091706A (ko) | 염화나트륨으로 안정화된 에타너셉트 제형 | |
| RU2018119765A (ru) | Инъекционные препараты на основе ботулотоксина и способы их применения, обеспечивающие длительное терапевтическое и косметического действие | |
| JP2016532698A (ja) | インスリン分泌性ペプチドの安定な水性非経口医薬組成物 | |
| KR20150030704A (ko) | 육안으로 보이지 않는 입자의 현저한 감소를 나타내는 에타너셉트 제형 | |
| HK1207577A1 (en) | Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain | |
| JP2019509311A5 (enExample) | ||
| RU2017101667A (ru) | Фармацевтические композиции | |
| MX2017012506A (es) | Composicion farmaceutica para la prevencion y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteina de fusion en la cual el peptido que penetra el tejido y la preparacion del factor de crecimiento endotelial antivascular se fusionan. | |
| EP2358395A4 (en) | METHOD AND FORMULATION FOR REDUCING THE AGGREGATION OF A MACROMOLECULUM UNDER PHYSIOLOGICAL CONDITIONS | |
| Volovat et al. | Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer receiving chemotherapy | |
| JP2019203011A (ja) | 可溶性Ｆｃ受容体の高濃度製剤 | |
| BR112013005763B1 (pt) | Injeção de 5a-androstano-3ss, 5, 6ss-triol e método para prrparação da injeção | |
| CA2928311A1 (en) | Formulation for gonadotropins | |
| WO2014165829A3 (en) | Nanoparticle formulations | |
| US11229702B1 (en) | High concentration formulations of adalimumab | |
| UA115333C2 (uk) | Склад есмололу для парентерального введення | |
| JP6204349B2 (ja) | 注射剤用組成物 | |
| EA201791409A1 (ru) | Препараты для инъекций парацетамола |